Introduction
Meningiomas are neoplasms of the leptomeninges covering the brain and the spinal cord. With *20% of all primary intracranial tumors, they are among the most common tumors of the human nervous system (Kleihues and Cavenee, 2000) . Although there is a large amount of evidence for involvement of the neuro®bromatosis type 2 (NF2) gene in tumor growth, 40% of the meningiomas show no mutation in the NF2 gene, indicating that other genes are involved in the tumorigenesis (Ruttledge et al., 1994; Akagi et al., 1995) .
A variety of tumors are known to elicit immune responses in patients bearing the tumor. Immunogenic tumor-associated antigens have been described primarily for malignant tumors including melanoma, breast cancer, colon cancer, ovarian cancer (Real et al., 1988; Ben-Mahrez et al., 1990; Gallagher et al., 1991; Disis et al., 1994; Disis and Cheever, 1996; Boon and Lloyd, 1997) . However, dierent studies have indicated that meningiomas are also capable of inducing an immune response in the host. In 1976, Pees and Seidel already described a cellular immune response against autologous and heterologous meningioma cells in the serum of patients (Pees and Seidel, 1976) . Another study concerning a cytotoxic immune response presents data suggesting that meningiomas can induce complex immunological responses in the host (Pees, 1979) . The presence of IgG in meningioma was shown by Tabuchi et al. (1979) . Expression of MHC class II and MHC class I molecules have also been detected in meningioma tissue (Becker and Roggendorf, 1989) .
Previously, we reported cloning of immunoreactive antigens expressed in meningioma, providing the ®rst evidence for the expression of immunogenic antigens in this tumor type (Heckel et al., 1997 (Heckel et al., , 1998 Comtesse et al., 1999) . The meningioma expressed antigens 6/11 (MGEA6/11; previously called MEA6/11) induced an immune response in the patient bearing the meningioma (Heckel et al., 1997) . Expression analysis on the mRNA level revealed constitutive expression of the MGEA6/11 in all human tissues tested. MGEA6 belongs to a multigene family with an active locus on chromosome 14q and at least nine pseudogenes on dierent chromosomes. The smaller MGEA11 is generated by alternative splicing of exon 19 of the MGEA6 gene (Comtesse et al., 2001) .
In this study we report that the immune response against MGEA6/11 is found in 41.7% (10/24) of meningioma and in 2/8 of glioblastoma patients, with no antibodies present in 12 sera of healthy persons, indicating that MGEA6/11 probably acts as a tumor antigen in these tumor types. We report that on the protein level, MGEA6/11 is overexpressed in meningioma and glioma tumor cells compared to the normal tissue. Immunohistochemical staining of tissue sections revealed reactivity of meningioma cells and tumor cells of glial origin, whereas no reactivity was found in the cellular elements of the normal control brain and only faint reactivity in normal leptomeninges. No expression was found in tumor cells of cerebral carcinoma metastases. Sequence analysis purported a membranic localization of the protein, which was con®rmed by Western-blot analysis of cellular fractions of MGEA6/ 11 expressing cells. Our ®ndings suggest that the immune response in glioma and meningioma patients may likely be attributed to overexpression of this gene at the protein level.
Results

Recombinant expression of MGEA6/11 in a eukaryotic expression system
To further characterize the meningioma expressed antigens 6 and 11 (MGEA6/11), we expressed the two variants in a recombinant eukaryotic expression system. As shown previously, cDNA for MGEA6 shows an open reading frame (ORF) of 2415 bp and cDNA for MGEA11 an ORF of 2286 bp, with the coding regions diering only in a 129 bp sequence (Heckel et al., 1997) . As most recently described, mRNA for MGEA11 probably results from alternative splicing of exon 19 of the MGEA6 gene on chromosome 14q (Comtesse et al., 2001) . Sequence analysis of the cDNA clones revealed a high number of codons rarely used in bacteria. Therefore, we used the baculovirus expression system to facilitate complete translation of the clones. After recombinant expression, the proteins were visualized by Western blot analysis using the serum of the autologous patient for detection. We determined molecular masses for MGEA6 of 110 kDa and for MGEA11 of 105 kDa (Figure 1a) . Deducting the fusion portion of 34AA (about 4 kDa), results in a molecular mass of 106 kDa for MGEA6 and of 101 kDa for MGEA11. This is in good accordance with the predicted theoretical molecular masses of 91 kDa for MGEA6 and 89 kDa for MGEA11. The minimal mass dierences can be attributed to post-translational modi®cation.
Humural immune response against MGEA6/11 is found in meningioma and glioma patients, not in healthy persons
We also used the baculovirus-expressed recombinant proteins to examine the immune response against MGEA6/11 in other patients bearing meningiomas. We tested 24 sera derived from patients with meningioma of dierent grading and histological subtype. An antibody reaction was detected with 10 of 24 (41.7%) meningioma sera. The immune response was not correlated with tumor grading or histological subtype of meningiomas (Tables 1 and 2 ). In detail, we found antibodies against MGEA6/11 in 4/10 sera from WHO grade I meningiomas including arachnothelial, transitional and secretory subtypes, in 5/12 sera from atypical meningiomas, and in one of two sera from anaplastic meningioma.
We further tested sera from patients with primary brain tumors of glial origin (Table 2) . We detected antibodies against MGEA6 in 2/8 sera from glioblastoma (WHO grade IV) patients ( Figure 1b ) and in one of two patients with WHO grade II astrocytomas. Sera derived from two patients with WHO grade III astrocytomas and from three patients with pilocytic astrocytomas did not react with MGEA6/11. When using 12 sera from healthy, tumor-free persons, in no case was an antibody response detected against MGEA6/11 (Figure 1c) . Additionally, for testing tumors derived from other embryonic origin, we tested six sera of patients with squamous cell lung carcinoma. In no case were antibodies against MGEA6/11 found. To obtain information about the protein structure of MGEA6/11, we analysed the amino acid sequences with several computer programs. The predicted domain structure is shown in Figure 2 . The amino acid sequence possesses a transmembrane domain (AA 39 ± 59) close to the N-terminus. Additionally, the amino acid sequence shows two coiled coil domains (AA 115 ± 261; 322 ± 496) . Within the ®rst one is located a heptad repeat of four leucine residues. The C-terminal region is characterized by a high percentage (22%) of proline residues including several polyproline stretches. Notably, the insertion found in MGEA6 also possesses a high amount of proline residues and shows high hydrophobicity.
Generation of polyclonal antibodies against MGEA6/11 via peptide immunization
To investigate the MGEA6/11 expression at the protein level, we generated polyclonal rabbit antibodies against MGEA6/11. We synthesized a peptide from the Cterminus of MGEA6/11. For immunization, the peptide was coupled with an additional N-terminal cysteine residue to keyhole limpet hemocyanine. One week after each immunization, the serum was tested for antibodies against MGEA6/11 by Western blot analysis using the recombinant proteins from the baculovirus-expressing clones. Positive serum was enriched for peptide-speci®c antibodies by anity puri®cation using a peptide-coupled sepharose column. Speci®city of the peptide-enriched serum was shown by Western blot analysis ( Figure 3a ).
Western blot analysis shows overexpression of MGEA6/11 in meningioma and glioblastoma compared to normal brain
The peptide-puri®ed, polyclonal antibody was used to examine MGEA6/11 expression in dierent tissue lysates by Western blot analysis. We examined the MGEA6/11 expression of 19 human meningiomas of dierent WHO grading, a pilocytic astrocytoma (WHO I), an oligoastrocytoma (WHO II), three glioblastomas (WHO IV), and an anaplastic oligodendroglioma (WHO III). Additionally we tested three normal brain samples, two derived from an autopsy case (cerebellum and frontal lobe) and one derived from the neurochirurgical resection of meningioma H 560. Table 3 summarizes the protein expression analysis. As shown in Figure 3b , a *106 kDa protein was detected in all tested meningiomas and brain tumors. In most samples a second lighter signal, about 3 ± 5 kDa smaller, was detected. This protein corresponds to the smaller variant MGEA11. Notably, the expression level of the larger MGEA6 protein is higher than that of the smaller variant in normal brain and meningioma grades I and II. Only the grade III meningiomas show an equivalent expression of both variants. The level of protein expression in normal human brain samples is signi®cantly lower than in the examined brain tumor tissues.
When the peptide used to generate the MGEA6/11 antibody is incubated with the anity-puri®ed serum, it eectively blocks the binding demonstrating the speci®city of the puri®ed MGEA6/11 polyclonal antibody. To con®rm that the signals are not generated by a non-speci®c interaction with the secondary antibody, we incubated the Western blot with the anti-rabbit secondary antibody only. No signal was revealed with the anti-rabbit secondary antibody (data not shown). We also used the peptide-puri®ed, polyclonal rabbit serum to investigate MGEA6/11 immunohistochemically on dierent frozen tumor sections (Figure 4) . Table  1 summarizes the immunohistochemical staining results. All meningiomas demonstrated, independent of the WHO grading, reactivity to the MGEA6/11 polyclonal antibodies. While in some meningiomas all tumor cells were positive for MGEA6/11, others showed rather patchy reactivity. Also positive for MGEA6/11 expression were brain tumors of glial origin. We tested a circumscribed glioma (pilocytic astrocytoma), further diverse diuse gliomas and an atypical teratoid rhabdoid tumor. In the tumor cells of two examined primary cerebral non-Hodgkin's lymphomas, no MGEA6/11 expression was detected. Furthermore, brain metastases of dierent carcinomas were investigated. In contrast to tumors derived from the epithelium, which lacked any MGEA6/11-reactivity, a brain metastasis of a malignant melanoma, showed focal Normal astrocytes, in contrast, showed no MGEA6/11 reactivity. Leptomeninges of two autopsy cases showed faint reactivity of the arachnoid cells (Figure 4) . In all cases where immunoreactivity was observed, MGEA6/11 was localized in the cytoplasm. No nuclear staining was detected throughout. Also, there was partially enhanced staining of the cytoplasmic membrane, indicating membranic localization of this antigen. In some samples, there seemed to be a globular perinuclear staining, comparable with the Golgi-®eld.
Verification of membranic localization of MGEA6/11
To determine subcellular localization of MGEA6/11, we prepared cellular fractions from the glioblastoma cell line TX3868, which expresses the MGEA6/11 protein. Nucleus-, cytosol-and membrane fractions were analysed by Western-blot using the anti-MGEA6/ 11 antibody ( Figure 5 ). Speci®city of fractions was (Figure 2 ).
Discussion
Previously, the meningioma expressed antigens 6 and 11 (MGEA6/11) were identi®ed by immunoscreening a meningioma cDNA expression library with autologous serum (Heckel et al., 1997) . Here, we report that antibodies against MGEA6/11 are found in 41.7% of meningioma patients, without correlation to tumor grade or histological subtype. Furthermore, we showed that 2/8 glioblastoma patients and 1/2 of patients with astrocytoma grade II had antibodies against MGEA6/ 11. There was no antibody response in two sera from patients with anaplastic astrocytomas (WHO grade III), in three patients with pilocytic astrocytoma and in 12 sera from healthy persons. Our data show that MGEA6/11 can induce antibody response in meningioma patients and in patients with diuse gliomas. In addition, our Western blot studies revealed overexpression of MGEA6/11 in meningioma and glioma tissues compared to normal brain. Notably, the increased expression was detected in all examined meningiomas, independent of the WHO grading and seems not to be correlated with the grade of malignancy. Our immunohistochemical studies of dierent frozen tumor sections support the Western blot data. Reactivity against MGEA6/11 was shown in meningioma tumor cells and in tumor cells of brain tumors with glial origin, whereas no reactivity was found in normal astrocytes and faint reactivity in normal leptomeninges. The faint expression found in normal brain by Western blotting is likely attributable to higher sensitivity of Western blot in comparison to immunohistochemical staining. In brain metastasis of tumors derived from the epithelium, MGEA6/11 was not detected. In neural crest derivatives, however, such as the brain metastasis of a malignant melanoma, patchy reactivity was noted. These results are consistent with the idea that overexpression of MGEA6/11 is restricted to tumors of neuroectodermal origin.
There is a long standing concept that brain is an immunologically privileged site (Barker and Billingham, 1977) . However, meningiomas as tumors derived from leptomeninges covering the brain and the spinal cord, are not protected by the blood-brain barrier. As for gliomas, the astrocytes as the essential part of the blood-brain barrier are aected by tumorigenesis. Our data suggest that antibody-response against MGEA6/11 is not patient-speci®c and that MGEA6/11 frequently elicits an immune response in patients with primary intracranial tumors. We postulate that the observed overexpression of MGEA6/11 in the tumor cells may cause the immune response detected in meningioma and glioma patients. Interestingly, overexpressed oncogenic proteins are known to represent potential tumor antigens. C-erbB-2, for example, is overexpressed in human tumors, especially in breast carcinoma, and antibodies against this overexpressed protein have been detected in several patient sera (Pupa et al., 1996) . Autoantibodies against the L-myc oncogene, which is known to be overexpressed in tumors with neuroendocrine characteristics, have been identi®ed in sera from patients with small cell lung cancer (Yamamoto et al., 1996) . However, these studies have not established a correlation between overexpression and induction of immune response for the same tumor. Here we showed that the observed overexpression of MGEA6/11 is frequently associated with an antibody response. However, various studies propose alternative mechanisms, causing the induction of immune responses (Disis and Cheever, 1996; Boon and Lloyd, 1997) .
A question is what biological function MGEA6/11 may have during tumor development. Prediction of the protein structure of MGEA6/11 shows an N-terminal transmembrane domain. Membranic localization was con®rmed by Western-blot analysis of cellular fractions of a MGEA6/11 expressing cell line. Additionally, from the protein structure prediction, some other domains were identi®ed which could be involved in protein ± protein interactions (Figure 2 ). For example, interactions mediated by proline-rich regions are described for WW domains found in proteins of signal transduction pathways (Marcias et al., 1996) . Coiled-coil domains are known to be present in structure-forming proteins and also in protein-binding regions. These data suggest that MGEA6/11 could have some binding partners. Together with the membranic localization, this makes MGEA6/11 probably involved in signaling pathways.
Materials and methods
Recombinant protein expression in Baculovirus Expression system
Expression of MGEA6 and MGEA11 was performed using Xpress System Baculovirus Protein Expression system (Invitrogen). In brief, open reading frames of MGEA6 and Figure 5 Cellular localization of MGEA6/11 by Western-blot analysis of cell fractions of MGEA6/11 expressing glioblastoma cell line TX3868. The speci®city of the cell fractions was con®rmed by Ki-67, known to be localized in the nucleus and N-cadherin, known to be localized at the cytoplasmic membrane. Incubation with anti-MGEA6/11 serum con®rms the localization of MGEA6/11 to the membranic fraction MGEA11 were cloned into the pBlueBacHis2A expression vector (Invitrogen). Transformation into SF158 cells was performed using the Bac-N-Blue Transfection Kit (Invitrogen). Plaque assay for puri®cation of recombinant virus was performed twice. High titer virus stocks were generated and used for SF158 cell infection. Cells were harvested 46 h postinfection and stored at 7758C. Cell pellets were resuspended in lysis buer (20 mM Sodium phosphate, pH 7.0; 100 mM NaCl; 2% NP-40; 1% Complete, EDTA-free Protease Inhibitor Cocktail (Boehringer Mannheim)). Lysis was performed for 2 h on ice. Cell debris was collected (20 min, 13 500 r.p.m., in a Hermle Z 323 K centrifuge at 48C). Lysate was mixed with Roati-Load1 (Roth) and stored at 7758C.
Protein structure prediction
Protein structure prediction was performed with the SMART-Simple Molecular Architecture Research Tool (http://smart.embl.heidelberg.de), TMHMM 2.0 (http:// www.cbs.dtu.dk/services), TMpred (http://wwwch.embnet. org/software) and the algorithms PROSITE and BEAUTY.
Peptide synthesis
A peptide from the C-terminal amino acids 776 to 795 of MGEA6/11 was synthesized by the Fmoc method of solid phase peptide chemistry (Merri®eld, 1963) on a Milligen/ Biosearch 9050 Pep-synthesizer. Cleavage of the peptides from the resin and removal of the protecting groups were achieved by treating the peptide with 90% tri¯uoroacetic acid, 2.5% phenol, 2.5% 1,2-ethanedithiol, 1% triisopropylsilane (all from Sigma) and 5% water.
Polyclonal antibodies
Antibodies were generated against the peptide plus an additional amino-terminal cysteine-residue. The peptide was coupled to keyhole limpet hemocyanine that had been activated with N-succinimidyl-3-maleinimido-propionate (Fulka). To obtain antibodies, rabbits (bastards) were immunized by subcutaneous injections of 300 mg of coupled peptide emulsi®ed in Freund's complete adjuvant (Sigma) (Harlow and Lane, 1998) . The immunization was repeated two times at 2-week intervals with the same amount of coupled peptide in Freund's incomplete adjuvant. The rabbits were bled 8 ± 10 days after the immunizations.
Affinity purification of the polyclonal antibodies
The peptide-speci®c polyclonal antibodies were anity puri®ed using the HiTrap NHS-activated anity columns from Amersham Pharmacia Biotech according to instruction manual. Ten milligrams of peptide were coupled to the NHSactivated Sepharose column, and puri®cation was performed according to Harlow and Lane (1988) . In brief, 5 ml of the rabbit serum were diluted 1 : 10 with 10 mM Tris, pH 7.5, and the diluted serum was applied two times to the equilibrated column. Antibodies were eluted with 100 mM glycine, pH 2.5. Fractions were immediately neutralized with 1 M Tris, pH 8. Finally, buer exchange against PBS pH 7.5 was performed using NAP-25 Columns (Amersham Pharmacia Biotech). Final volume was 14 ml.
Tumor tissues and sera
The tumor tissues and sera were used with consent by the patients. Tissue samples were frozen in liquid nitrogen immediately after surgery and then stored at 7708C. Serum was taken from patients at the day of surgery and stored at 7708C.
Tissue lysates
Frozen tissues were homogenized in sample buer (6% SDS; 125 mM Tris pH 6.8; 10% (v/v) mercaptopropanediol; 10% (v/v) glycerol; 1% Complete, EDTA-free Protease Inhibitor Cocktail (Boehringer Mannheim)) using an ultra-turrax. Samples were incubated 10 min at room temperature. Cell debris was separated (20 min, 3000 r.p.m. in a Hermle Z 323 K centrifuge at 48C), and the lysate was soni®ed (two times, 10 s). The debris was separated (20 min, 13 500 r.p.m.) again, and the supernatant was stored at 7758C. The protein concentration of the tissue lysates was examined with the Bio-Rad protein assay.
Western blot analysis
Proteins were separated by electrophoresis on a 10% SDSpolyacrylamide gel at 25 mA for 3 h. Proteins were transferred to Hybond-P membrane (Amersham Pharmacia Biotech) by electroblotting at 500 mA for 3 h. Membranes were blocked in 16PBS; 0.5% dry-milk for 1 h at room temperature. Peptide-speci®c, anity-puri®ed rabbit serum was diluted 1:50, human preabsorbed patient serum 1:100 ± 1:500 in 16PBS; 0.5% dry-milk and incubated overnight at 48C. After washing three times for 10 min each in 16PBS, the membrane was hybridized with the secondary antibody (goat anti-rabbit or goat anti-human IgG Fc-speci®c antibody conjugated to peroxidase (Dianova)) 1 : 5000 in 16PBS, 5% dry-milk for 1 h at room temperature. Detection was carried out using the ECL detection reagent (Amersham Pharmacia Biotech) according to the manufacturer's instructions.
Tissue preparation for immunohistochemistry
Fresh tissue samples were snap frozen in nitrogen cooled isopentane and protected from lyophilization by coating them with aqueous 2% Tragant (Merck, Germany). For any case included in the study, at least one hematoxylin-eosin-stained 8 mm thick section plus serial unstained sections were available. After cutting, they were allowed to air dry at room temperature for 5 min, were ®xed by immersion in 48C cold Zamboni's ®xative for 10 min (PBS with 15% (v:v) twice ®ltered saturated picric acid and 2% (w:v) paraformaldehyde, ®nal pH 7.3), thereafter thoroughly washed under running tap water for 10 min, and again air dried. They were kept frozen at 7808C until use.
Immunohistochemistry
Endogenous peroxidase activity was quenched by immersing the sections in 3% hydrogen peroxide in methanol for 30 min. For immunohistochemistry, the optimal dilution of the peptide-speci®c, anity puri®ed polyclonal antibody to MGEA6/11 was 1 : 5. Both the background reducing antibody diluent (S 3022) and the components of the detection systems, including color substrate, were purchased from DAKO, Hamburg, Germany. Incubation of the sections with the primary antibody was done in a moist chamber at 378C for 30 min. Optimal detection was achieved with biotin labeled swine F(ab') 2 fragments to rabbit immunoglobulins (E 0431) (1 : 200, 378C, 10 min) followed by a second incubation step with horseradish peroxidase (HRP) con-jugated streptavidin (P 0397) (1 : 300, 378C, 20 min). After each incubation step, the sections were thoroughly rinsed in phosphate buered saline (PBS). Reaction products were visualized with diaminobenzidine as the color substrate (DAB Plus substrate solution, 1 : 50; K 3468). Counterstaining of the nuclei was done with Harris' hematoxylin followed by covering the slides with an organic mounting medium and cover slips after dehydration with alcohol and xylol.
Preparation of cellular fractions
Cells were rinsed twice with cold PBS and collected (10 min; 1200 r.p.m.). The cell pellet was washed and then lysed in 2 volumes of lysis buer (10 mM HEPES (pH 7.9), 10 mM KCl, 3 mg/ml Aprotinin) 5 min at 48C. The lysate was homogenized in a Dounce homogenizer (20 strokes) and centrifuged at 1500 r.p.m. for 15 min at 48C to obtain a nuclear pellet. The supernatant was collected, adjusted with 5 M NaCl to a concentration of 0.15 M and centrifuged for 1 h at 38 000 r.p.m. and 48C (Centrikon T-2060, Kontron). The supernatant contained the cytosolic fraction. The pellet was resuspended with NTENT-buer (150 mM NaCl, 10 mM Tris/Cl (pH 8), 1 mM EDTA (pH 8), 3 mg/ml Aprotinin, 0.1 mM PMSF, 0.1 mM NaNO 4 , 10 mM NaF, 50 mM glycerolphosphate, 1% Triton X-100, 1% NP40) and centrifuged at 38 000 r.p.m. for 1 h at 48C. The supernatant was referred to as membrane fraction. The nuclear pellet (see above) was washed with buer A (10 mM HEPES, 10 mM KCl, 1.5 mM MgCl 2 , 5 mM DTT, 0.5 mM PMSF) and resuspended in three volumes buer B (20 mM HEPES, 450 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 5 mM DTT, 0.5 mM PMSF, 20% Glycerol), incubated for 30 min on ice and centrifuged for 20 min at 15 000 r.p.m. and 48C. The supernatant was referred to as nuclear extract.
